Aspirin reduces the outcome of anticancer therapy in Meth A-bearing mice through activation of AKT-glycogen synthase kinase signaling

Molecular Cancer Therapeutics

Volumn 5, Issue 5, 2006, Pages 1318-1324

  Di Palma, Antonella ^a   Matarese, Giuseppe ^a   Leone, Vincenza ^a   Di Matola, Tiziana ^a   Acquaviva, Fabio ^a   Acquaviva, Angela Maria ^a   Ricchi, Paolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3 FLUOROPHENYL) 5,5 DIMETHYL 4 (4 METHYLSULFONYLPHENYL) 2(5H) FURANONE; 3 METHYLCHOLANTHRENE; ACETYLSALICYLIC ACID; CISPLATIN; ETOPOSIDE; GLYCOGEN SYNTHASE KINASE 3; INDOMETACIN; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; FIBROSARCOMA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASPIRIN; ETOPOSIDE; FEMALE; FIBROSARCOMA; GLYCOGEN SYNTHASE KINASES; METHYLCHOLANTHRENE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 33745101677     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0473     Document Type: Article

References (35)

1. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998;90:1529-36.
2. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(κ)B kinase-β. Nature 1998;96:77-80.
3. Xu XM, Sansores-Garcia L, Chen XM, et al. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci U S A 1999;96:5292-7.
4. Pillinger MH, Capodici C, Rosenthal P, et al. Modes of action of aspirin-like drugs: salicylates inhibit ERK activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci U S A 1998;95:14540-5.
5. Dong Z, Huang C, Brown RE, Ma WY. Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. J Biol Chem 1997;272:9962-70.
6. Ricchi P, Pignata S, Di Popolo A, et al. Effect of aspirin treatment on cell proliferation and differentiation of colon adenocarcinoma Caco-2 cells. Int J Cancer 1997;73:880-4.
7. Aas AT, Tonnessen TI, Brun A, Salford LG. Growth inhibition of rat glioma cells in vitro and in vivo by aspirin. J Neurooncol 1995;24:171-80.
8. Redondo S, Santos-Gallego CG, Ganado P, et al. Acetylsalicylic acid inhibits cell proliferation by involving transforming growth factor-β. Circulation 2003; 107:626-9.
9. Grilli M, Pizzi M, Memo M, Spano PF. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation. Science 1996;274:1383-5.
10. 2 in HeLa cells. Free Radic Res 2003; 37:1267-76.
11. Hsu CS, Li Y. Aspirin potently inhibits oxidative DNA strand breaks: implications for cancer chemoprevention. Biochem Biophys Res Commun 2002;293:705-9.
12. Shi X, Ding M, Dong Z, et al. Antioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF-κB activation, and TNF-α production. Mol Cell Biochem 1999; 199:93-102.
13. Chen N, Ma W, Dong Z. Inhibition of arsenite-induced apoptosis by aspirin. Anticancer Res 2001;21:3247-51.
14. Sairam K, Saravanan KS, Banerjee R, Mohanakumar KP. Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 2003;966:245-52.
15. Mattie MD, Freedman JH. Protective effects of aspirin and vitamin E (α-tocopherol) against copper- and cadmium-induced toxicity. Biochem Biophys Res Commun 2001;285:921-5.
16. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109:1321-6.
17. Vartiainen N, Goldsteins G, Keksa-Goldsteine V, et al. Aspirin inhibits p44/42 mitogen-activated protein kinase and is protective against hypoxia/reoxygenation neuronal damage. Stroke 2003;34:752-7.
18. Ricchi P, Di Matola T, Ruggiero G, et al. Effect of non-steroidal anti-inflammatory drugs on colon carcinoma Caco-2 cell responsiveness to topoisomerase inhibitor drugs. Br J Cancer 2002;86:1501-9.
19. Ricchi P, Palma AD, Di Matola T, et al. Aspirin protects Caco-2 cells from apoptosis after serum deprivation through the activation of a phosphatidylinositol 3-kinase/AKT/p21Cip/WAF1 pathway. Mol Pharmacol 2003;64:407-14.
20. Srivastava PK, DeLeo AB, Old LJ. Tumor rejection antigens of chemically induced sarcoma of inbred mice. Proc Natl Acad Sci U S A 1986;83:3407-11.
21. DeLeo AB, Shiku H, Takahashi T, John M, Old LJ. Cell surface antigens of chemically induced sarcoma of the mouse. J Exp Med 1976;146:720-34.
22. Li M, Wang X, Meintzer MK, et al. Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3β. Mol Cell Biol 2000;20:9356-63.
23. Loberg RD, Vesely E, Brosius FC III. Enhanced glycogen synthase kinase-3β activity mediates hypoxia-induced apoptosis of vascular smooth muscle cells and is prevented by glucose transport and metabolism. J Biol Chem 2002;277:41667-73.
24. Din FV, Dunlop MG, Stark LA. Evidence for colorectal cancer cell specificity of aspirin effects on NFκB signalling and apoptosis. Br J Cancer 2004;91:381-8.
25. Leinninger GM, Backus C, Uhler MD, et al. Phosphatidylinositol 3-kinase and Akt effectors mediate insulin-like growth factor-I neuro-protection in dorsal root ganglia neurons. FASEB J 2004;18:1544-6.
26. Yu X, Rajala RV, McGinnis JF, et al. Involvement of insulin/ phosphoinositide 3-kinase/Akt signal pathway in 17β-estradiol-mediated neuroprotection. J Biol Chem 2004; 279:13086-94.
27. Pommier Y, Sordet O, Antony S, et al. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934-49.
28. Hovelmann S, Beckers TL, Schmidt M. Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells. Br J Cancer 2004;90:2370-7.
29. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004;428:332-7.
30. Beurel E, Kornprobst M, Blivet-Van Eggelpoel MJ, et al. GSK-3β inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression. Exp Cell Res 2004;300:354-64.
31. Lochhead PA, Coghlan M, Rice SQ, Sutherland C. Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phos-phoenolypyruvate carboxykinase gene expression. Diabetes 2001;50:937-46.
32. Plotkin B, Kaidanovich O, Talior I, Eldar-Finkelman H. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J Pharmacol Exp Ther 2003;305:974-80.
33. Ricchi P, Zarrilli R, di Palma A, Acquaviva AM. Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer 2003;88:803-7.
34. Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 2001;108:585-90.
35. Insel PA. The salicylates, in Goodman and Gilman's, the pharmacological basis of therapeutics. In: Hardman JG, Limbird LE, Molinoff RW, editors. McGraw-Hill Milan, Italy; 2001. p. 696-703.